NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1910.00 7.60 (0.40%)

52W high on Jul 31, 2026

2.3M NSE+BSE Volume

NSE 24 Aug, 2026 3:14 PM (IST)

458,273

Market Cap

Market Leader

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Search Inside the pdf :

Sun Pharmaceutical Industries Ltd.

04 Aug 2026

1910.00

0.40%

Key Investment Thesis

Accumulate: Sun Pharmaceutical Industr...

Target

Deven Choksey

The outlook for Sun Pharma remains constructive, supported by the continued strength of its India formulations business, expanding specialty portfolio, and disciplined investment in innovation.

Promoters pledged 0.23% of shares in last quarter. Total pledge stands at 1.65% of promoter holdings

Sun Pharmaceutical Industries Ltd.

01 Aug 2026

1910.00

0.40%

Specialty and branded lead the way

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharma (SUNP) delivered in-line revenue/EBITDA in 1QFY27, whereas adjusted PAT came in higher than expected (11% beat), led by higher other income.

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1791.7

Sun Pharmaceutical Industries Ltd.

27 May 2026

1910.00

0.40%

Specialty Scale-Up and Organon Integration Strengthen Long-Term Growth Visibility

Accumulate: Sun Pharmaceutical Industr...

Target

Deven Choksey

Sun Pharma has crossed a critical inflection point. For the first time, its US Innovative Medicines franchise — led by Ilumya, Unloxcin, Leqselvi, and Cequa — is the larger US business, eclipsing generics.

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1791.7

Sun Pharmaceutical Industries Ltd.

25 May 2026

1910.00

0.40%

Sun Pharmaceutical Industries (SUNP IN) Q4FY26 Result Update Traction from Domestic & Specialty business continues BUY

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Sun Pharma (SUNP) Q4FY26 EBIDTA growth of 6% YoY was lower than our estimates led by higher opex. Key markets like India and specialty continue to report strong growth. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Its recent acquisition of Organon in all cash deal provides an entry into biosimilars and diversify its branded generics portfolio. The deal is EPS accretive from Year 1 and will see significant EPS accretion. Company has managed to enjoy higher multiple compared to peers given its exposure to high growth branded...

Deven Choksey increased Accumulate price target of Sun Pharmaceutical Industries Ltd. to 2218.0 on 04 Aug, 2026.

Sun Pharmaceutical Industries Ltd.

24 May 2026, 12:00AM

1910.00

0.40%

Sun Pharma (BUY): Higher R&D spend leads to better sales across geographies

Buy: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT came 1.4%/-13.5%/-4.3% below estimates. Gross Margin was 103 bps higher; EBITDA Margin 416 bps below estimates

Sun Pharmaceutical I.. has an average target of 2085.12 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

28 Apr 2026

1910.00

0.40%

Sun Pharma

Hold: Sun Pharmaceutical Industr...

Recommendation Target

ICICI Direct

company with 43 manufacturing sites at its disposal addressing segments like specialty products, branded generics, complex generics, pure generics and APIs. Sun is ranked No. 1 in domestic formulations. It enjoys a leadership...

Promoters pledged 0.23% of shares in last quarter. Total pledge stands at 1.65% of promoter holdings

Sun Pharmaceutical Industries Ltd.

28 Apr 2026

1910.00

0.40%

Sun Pharmaceutical Industries (SUNP IN) Event Update Acquires Organon for USD 11.75bn BUY

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Sun Pharmaceutical Industries (SUNP)'s acquisition of Organon at an EV of $11.75bn in all cash deal makes its largest acquisition so far. This will enable SUNP an entry into biosimilars and scale up its women's health presence, further diversifying its branded generics portfolio. The deal also strengthens its access to new markets like China. Though SUNP has acquired company similar to its size at 30% of its value, the growth profile of Organon is muted/flattish over last 2-3 years as compared to 13-15% growth profile for SUNP. On call mgmt. has highlighted for better growth profile of acquired profile through more in licensing deals, new line extensions, cost synergies and tapping...

Number of FII/FPI investors decreased from 1246 to 1233 in Jun 2026 qtr

Sun Pharmaceutical Industries Ltd.

28 Apr 2026

1910.00

0.40%

Taking a giant leap

Buy: Sun Pharmaceutical Industr...

Target

ICICI Securities Limited

Sun Pharma (Sun) has entered into a definitive agreement to acquire US-based Organon for USD 11.75bn, of which USD 3.99bn would be paid in cash to purchase total outstanding equity at USD 14/share.

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1791.7

Sun Pharmaceutical Industries Ltd.

28 Apr 2026

1910.00

0.40%

Organon acquisition – Transformational fit, disciplined math

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharma’s (SUNP) proposed acquisition of New Jersey-based Organon will provide several advantages for SUNP in terms of portfolio expansion, healthcare professional (HCP) connect, and geographical reach.

Sun Pharmaceutical Industries Ltd. is trading above its 200 day SMA of 1791.7

Sun Pharmaceutical Industries Ltd.

28 Apr 2026

1910.00

0.40%

Organon acquisition – Key investor concerns addressed

Buy: Sun Pharmaceutical Industr...

Target

Emkay

Sun’s Organon acquisition marks a clear departure from its recent acquisition template – multiple sub-USD500mn assets over the years vs adding a company of its own scale as part of a single acquisition.

Sun Pharmaceutical I.. has an average target of 2085.12 from 8 brokers.

Is Sun Pharmaceutical Industries Ltd. worth buying?

1609 Votes:

Buy 75.45%

Sell 15.66%

Hold 8.89%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf